WallStreetZenWallStreetZen

NYSEMKT: CHRO
Chromocell Therapeutics Corp Earnings & Revenue

CHRO earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$9.0M
Current Profit Margin
0%

CHRO Return on Equity

Insufficient data to display

Be the first to know when CHRO announces earnings.

CHRO Return on Assets

Current Company
-848.3%
Current Industry
3.2%
CHRO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CHRO Return on Capital Employed

Current Company
-697.42%
Current Industry
-42.4%

CHRO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CHRO$0.00-$7.88M-$8.98MN/AN/A
KA$5.16M-$16.76M-$17.89M-5.64%N/A
ALLR$0.00-$11.78M-$20.94MN/AN/A
ABVC$25.36k-$9.22M-$12.62M-98.72%N/A
ADXN$1.55M-$11.94M-$12.62M-16.42%N/A

Chromocell Therapeutics Earnings & Revenue FAQ

What were CHRO's earnings last quarter?

Chromocell Therapeutics (NYSEMKT: CHRO) reported Q1 2024 earnings per share (EPS) of -$0.55, up 36.78% year over year. Total Chromocell Therapeutics earnings for the quarter were -$2.56 million. In the same quarter last year, Chromocell Therapeutics's earnings per share (EPS) was -$0.87.

If you're new to stock investing, here's how to buy Chromocell Therapeutics stock.

What was CHRO's earnings growth in the past year?

As of Q2 2024, Chromocell Therapeutics's earnings has grown year over year. Chromocell Therapeutics's earnings in the past year totalled -$8.98 million.

What was CHRO's revenue last quarter?

Chromocell Therapeutics (NYSEMKT: CHRO) reported Q1 2024 revenue of $0.00 up N/A year over year. In the same quarter last year, Chromocell Therapeutics's revenue was $0.00.

What was CHRO's revenue growth in the past year?

As of Q2 2024, Chromocell Therapeutics's revenue has grown null year over year. Chromocell Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.